3000例HBsAg携带者肝癌高危人群10年随访结果分析  

Analysis of 10-year Follow-up Results of Liver Cancer High-risk Group of 3000 Cases of HBsAg Carriers

作　　者：黄新 施燕乐 张姝婧 

机构地区：[1]启东市人民医院启东肝癌防治研究所,江苏启东226200

出　　处：《系统医学》2017年第16期102-104,共3页Systems Medicine

摘　　要：目的通过长期随访,证实HBsAg携带者发生肝癌高危险性为HBV感染群体提供及时的健康信息,为肝癌病因研究,早诊早治生物标志的研究及预防研究提供了宝贵的基础性资料和实验证据资料。方法对3 000例HBsAg携带者从2008—2017年进行了10年全程随访观察,主要观察肝功能系列、甲胎蛋白(AFP)、两对半、B超检查结果等指标。结果①3 000例PHC世界标化发病率为553.78/10万,是同期自然人群的5.76倍。②10年间肝癌发病率虽有波动但经χ~2检验差异无统计学意义(χ~2=0.014,P=0.085 6)。③20~65岁年龄段肝癌发病率,20岁开始有肝癌发生,45岁组PHC发病率最高为1 298.7/10万,其次是40岁组和60岁组。④ALT异常率2008—2017年有上升趋势(χ~2=81.61,P=0.000 1)ALT异常率(45~100 U/L)占97.56。⑤AFP阳性率从2008—2017年的10年间波动不大,差异无统计学意义。AFP阳性率与ACT异常率呈相关性(r>0.05,P<0.05)。结论 HBsAg携带者肝癌高危人群中对于ALT低水平异常者和AFP低浓度阳性患者持续进行定期的检查具有很大的必要性,也对肝癌的早诊早治起到了关键性作用。Objective To prove the liver cancer high risk of HBsAg carriers thus providing timely healthy information and providing valuable basic data and experimental data for the research of causes of liver cancer and early diagnosis and early diagnosis of biology markers. Methods 3 000 cases of HBsAg carriers were followed up for 10 years from2008 to 2017, and the liver function series, AFP, two half-and-half and B ultrasound examination results were mainly observed. Results The PHC world standardized incidence rate of 3 000 cases was 5 537.8/100 thousand, 5.76 times of natural group at the same period, and 10-year liver cancer incidence rate was fluctuated without statistical significance（χ~2=0.014 P=0.085 6）, and the 20~65 years old was the liver cancer incidence age, and the liver cancer has occurred since 20 years old, but the PHC incidence rate in the 45 years old group was the highest, reaching 1 298.7/100 thousand, followed by the 40 years old group and 60 years old group, and the ALT abnormal rate showed an increasing trend from 2008 to 2017（χ~2=81.61 P=0.000 1）, and the ALT abnormal rate（45~100 U/L） was 97.56, and the AFP positive rate was slightly fluctuated from 2008 to 2017, without statistical significance, and the AFP positive rate was correlated with ACT abnormal rate（r〉0.05, P〈0.05）. Conclusion It is very necessary for liver cancer high-risk group of HBsAg carriers to conduct the regular examination of ALT low level abnormal patients and AFP low concentration positive patients, and it is also vital to the early diagnosis and early treatment of liver cancer.

关 键 词：肝癌 高危人群 乙肝表面 抗原携带者 10年随访分析 

分 类 号：R735.7[医药卫生—肿瘤]